OTCMKTS:ESALY

Eisai - ESALY Stock Forecast, Price & News

$46.45

-0.11 (-0.24%)

(As of 08/16/2022 12:00 AM ET)

Add

Compare

Today's Range: $46.20
▼
$46.45
50-Day Range: $37.90
▼
$46.56
52-Week Range: $36.88
▼
$85.10

Volume: 9,849 shs
Average Volume: 24,285 shs
Market Capitalization: $13.32 billion

P/E Ratio: 51.04
Dividend Yield: 2.28%
Price Target: N/A

About Eisai (OTCMKTS:ESALY) Stock

Eisai Co., Ltd. offers pharmaceutical products in Japan. It offers Aricept for the treatment of alzheimer's disease/dementia with Lewy bodies; Methycobal for the treatment of peripheral neuropathy; and Fycompa, an antiepileptic drug for the adjunctive treatment of partial-onset and primary generalized tonic-clonic seizures. The company also provides Lyrica for pain treatment; Dayvigo, an anti-insomnia drug for the treatment of adults with insomnia; Lenvima, an anticancer agent/molecular targeted medicine for the treatment of thyroid cancer, renal cell carcinoma in combination with everolimus, and hepatocellular carcinoma; and Halaven, an anticancer agent/microtubule dynamics inhibitor for the treatment of breast cancer and liposarcoma. In addition, it offers Pariet, a proton-pump inhibitor for the treatment of gastric and duodenal ulcers, reflux esophagitis, and eradication of Helicobacter pylori infections, etc.; Humira, a fully human anti-TNF-a monoclonal antibody for the treatment of autoimmune diseases, such as rheumatoid arthritis; and Chocola BB plus, a vitamin B2 preparation for rough skin and stomatitis, as well as various products, which include third-class OTC drugs, designated quasi-drugs, and food with nutrient function. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.

Receive ESALY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eisai and its competitors with MarketBeat's FREE daily newsletter.

ESALY Stock News Headlines

August 16, 2022 | investing.com

Eisai Co., Ltd. (4523)

August 6, 2022 | seekingalpha.com

Eisai Co., Ltd. (ESALY) Management on Q1 2023 Results - Earnings Call Transcript

August 6, 2022 | markets.businessinsider.com

Eisai is about to announce its earnings — here's what to expect

July 31, 2022 | americanbankingnews.com

Jefferies Financial Group Weighs in on Eisai Co., Ltd.'s FY2023 Earnings (OTCMKTS:ESALY)

July 29, 2022 | markets.businessinsider.com

Eisai Announces Key Executive Appointment for Alzheimer's Disease Leadership

July 28, 2022 | nasdaq.com

Biogen Stock: Clinical Wins Support a Bullish Thesis

July 22, 2022 | investing.com

Biogen leans on new Alzheimer's drug to calm investor worries

July 6, 2022 | seekingalpha.com

Biogen, Eisai's Alzheimer's therapy lecanemab gets FDA priority review

July 5, 2022 | investing.com

FDA decision on Eisai, Biogen Alzheimer's drug due in January

June 6, 2022 | seekingalpha.com

Biogen inks licensing deal for Parkinson’s disease candidate

May 30, 2022 | benzinga.com

Eisai Co (OTC:ESALY), Short Interest Report

May 16, 2022 | finance.yahoo.com

Neurologists React to CMS' Finalized NCD Decision on Anti-Amyloid Monoclonal Antibodies for Alzheimer's Disease - Yahoo Finance

May 13, 2022 | seekingalpha.com

Eisai Co., Ltd. (ESALF) CEO Haruo Naito on Q4 2022 Results - Earnings Call Transcript - Seeking Alpha

May 11, 2022 | businesswire.com

Amber Specialty Pharmacy Added to Eisai's LENVIMA® Network - Business Wire

May 11, 2022 | finance.yahoo.com

Amber Specialty Pharmacy Added to Eisai’s LENVIMA® Network - Yahoo Finance

May 5, 2022 | globenewswire.com

Global Insomnia Market Is Expected to Reach $6.3 Billion by 2030: Says AMR - GlobeNewswire

May 3, 2022 | investing.com

Biogen CEO to leave as Alzheimer's drug struggles

April 29, 2022 | barrons.com

Alzheimer’s Drugs Face a Crucial Test. It’s Unclear Whether Medicare Will Pay for Them. - Barron's

April 29, 2022 | marketwatch.com

Lilly's experimental weight-loss drug may be a 'multibillion-dollar opportunity' - MarketWatch

April 18, 2022 | investors.com

Biogen Stock: Why One Analyst Says It's 'Too Good To Ignore' - Investor's Business Daily

April 9, 2022 | seekingalpha.com

How might the CMS decision on Biogen's Aduhelm impact other Alzheimer's candidates?

April 8, 2022 | seekingalpha.com

Eisai to complete FDA submission of next Alzheimer’s drug in 1Q fiscal 2022

April 8, 2022 | seekingalpha.com

Biogen slips as analysts react to final Medicare decision on Alzheimer’s therapy

April 7, 2022 | seekingalpha.com

Biogen falls as Medicare officially limits coverage for Alzheimer’s drug

April 4, 2022 | nasdaq.com

Bear of the Day: Biogen (BIIB)

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ESALY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eisai and its competitors with MarketBeat's FREE daily newsletter.

ESALY Company Calendar

Last Earnings: 8/04/2021
Today: 8/16/2022
Fiscal Year End: 3/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: OTCMKTS
Industry: Private households
Sub-Industry: N/A
Sector: Medical
Current Symbol: OTCMKTS:ESALY
CUSIP: N/A
CIK: 948406
Web: www.eisai.co.jp
Phone: (133) 817-3700
Fax: 813-3811-6032
Employees: 11,322
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): $0.91
Trailing P/E Ratio: 51.04
Forward P/E Ratio: 32.48
P/E Growth: 2.45
Net Income: $426.79 million
Net Margins: 4.14%
Pretax Margin: 7.20%
Return on Equity: 3.85%
Return on Assets: 2.48%

Debt

Debt-to-Equity Ratio: 0.12
Current Ratio: 2.04
Quick Ratio: 1.73

Sales & Book Value

Annual Sales: $6.74 billion
Price / Sales: 1.98
Cash Flow: $2.71 per share
Price / Cash Flow: 17.16
Book Value: $23.94 per share
Price / Book: 1.94

Miscellaneous

Outstanding Shares: 286,766,000
Free Float: N/A
Market Cap: $13.32 billion
Optionable: Not Optionable
Beta: 0.42

Key Executives

Mr. Haruo Naito (Age 75)
CEO, Representative Corp. Officer & Director
Comp: $877.62k
Mr. Gary Hendler (Age 56)
Sr. VP & Pres of EMEA Region
Comp: $1.04M
Dr. Lynn D. Kramer FAAN (Age 72)
M.D., VP & Chief Clinical Officer - Alzheimer's Disease and Brain Health
Comp: $892.62k
Ms. Yanhui Feng (Age 50)
Sr. VP
Comp: $825.11k
Dr. Nadeem Sarwar Ph.D.
Pres
Mr. Tatsuyuki Yasuno (Age 54)
Sr. VP, CFO & Chief IR Officer
Mr. Kenta Takahashi (Age 63)
Exec. VP, Gen. Counsel & Intellectual Property Internal Audit
Mr. Yosuke Akita (Age 57)
VP, Chief Compliance Officer & Chief Information Security Officer
Ms. Sayoko Sasaki (Age 54)
VP of Corp. Communications & ESG
Mr. Teruyuki Masaka (Age 44)
VP & Chief HR Officer

Key Competitors

View All Competitors

ESALY Stock - Frequently Asked Questions

Should I buy or sell Eisai stock right now?: 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Eisai in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ESALY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ESALY, but not buy additional shares or sell existing shares.
View ESALY analyst ratings or view top-rated stocks.
How have ESALY shares performed in 2022?: Eisai's stock was trading at $56.82 on January 1st, 2022. Since then, ESALY shares have decreased by 18.3% and is now trading at $46.45.
View the best growth stocks for 2022 here.
How were Eisai's earnings last quarter?: Eisai Co., Ltd. (OTCMKTS:ESALY) issued its quarterly earnings data on Wednesday, August, 4th. The company reported $1.34 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.09 by $0.25. The business had revenue of $1.82 billion for the quarter. Eisai had a net margin of 4.14% and a trailing twelve-month return on equity of 3.85%.
Is Eisai a good dividend stock?: Eisai (OTCMKTS:ESALY) pays an annual dividend of $1.06 per share and currently has a dividend yield of 2.28%. The dividend payout ratio is 116.48%. Payout ratios above 75% are not desirable because they may not be sustainable. Based on earnings estimates, ESALY will have a dividend payout ratio of 74.13% next year. This indicates that the company will be able to sustain or increase its dividend.

What guidance has Eisai issued on next quarter's earnings?: Eisai issued an update on its FY 2023 earnings guidance on Friday, June, 10th. The company provided EPS guidance of $1.37-$1.37 for the period. The company issued revenue guidance of $6.03 billion-$6.03 billion.
What is Eisai's stock symbol?: Eisai trades on the OTCMKTS under the ticker symbol "ESALY."
How do I buy shares of Eisai?: Shares of ESALY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Eisai's stock price today?: One share of ESALY stock can currently be purchased for approximately $46.45.
How much money does Eisai make?: Eisai (OTCMKTS:ESALY) has a market capitalization of $13.32 billion and generates $6.74 billion in revenue each year. The company earns $426.79 million in net income (profit) each year or $0.91 on an earnings per share basis.
How many employees does Eisai have?: The company employs 11,322 workers across the globe.
How can I contact Eisai?: Eisai's mailing address is 4-6-10 Koishikawa Bunkyo-ku, Tokyo M0, 112-8088. The official website for the company is www.eisai.co.jp. The company can be reached via phone at (133) 817-3700 or via fax at 813-3811-6032.

This page (OTCMKTS:ESALY) was last updated on 8/17/2022 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here